MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis

Marjon, Katya, Cameron, Michael J., Quang, Phong, Clasquin, Michelle F., Mandley, Everton, Kunii, Kaiko, McVay, Michael, Choe, Sung +9 more·2016·Cell Reports
DOI 10.1016/j.celrep.2016.03.043

Cited by (499)

Items 401–499 of 499

  1. Biology of cancer: current insights and perspectives
    Sushruta S. Hakkimane, Santosh Laxman Gaonkar · 2023 · Elsevier eBooks
  2. PRMT5 inhibitors for lower-risk myelodysplasia: Is there anywhere to move?
    Andrej Terzic, David J. Curtis · 2023 · Leukemia Research
  3. RECENT ADVANCES IN TARGETING THE PRMT5/MTA COMPLEX
    Christopher R. Smith, Matthew A. Marx · 2023 · Medicinal chemistry reviews
  4. Targeting MTAP creates a therapeutic vulnerability to PARP inhibition in brain metastatic TNBC by disrupting MAT2A mediated methionine metabolism
    Zhenkun Lou, Xiangyu Zeng, Fei Zhao, Lingxin Zhang, Richard M. Weinshilboum, Kaixiong Tao · 2023 · Research Square
  5. Prognostic Value of Immunohistochemical Expression of MTAP and AKIP1 in IDH1 Mutant Astrocytoma
    Mona Mostafa Ahmed, Mohammed Lateef, Amira Elwan, Enas Fouad, Dalia Hamouda Elsayed, Hanim Magdy Abdelnour, Asmaa Abdullatif · 2023 · Asian Pacific Journal of Cancer Prevention
  6. Body Cavity Fluid Cytology
    Minhua Wang · 2023 · Springer eBooks
  7. Glutamine Addiction is Targetable via Altering Splicing of Nutrient Sensors and Epitranscriptome Regulators
    Jodie Bojko, Madhu Kollareddy, Marianna Szemes, Jacob Bellamy, Evon Poon, Ahmad Moukachar, Danny Legge, Emma E. Vincent, Nicholas Jones, Sally Malik et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  8. Drug Discovery for Chromatin Readers, Writers, Erasers, Remodelers and Epitranscriptomic Targets
    2024 · Royal Society of Chemistry eBooks
  9. Case Studies
    2024 · Royal Society of Chemistry eBooks
  10. Emerging Technologies for Epigenetic Drug Discovery
    2024 · Royal Society of Chemistry eBooks
  11. Highlights of Translational and Molecular Research Presented at the European Society for Medical Oncology Annual Meeting 2024
    Carolin Krekeler, Verena Turco, Annabel Helga Sophie Alig, Annalen Bleckmann, Michael Quante, Christoph Benedikt Westphalen, Kathrin Heinrich, Maryam Barsch · 2025 · Oncology Research and Treatment
  12. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
    Youyou Zhang, Mu Xu, Jiao Yuan, Zhongyi Hu, Junjie Jiang, Yanrong Sun, Jie Sheng Huang, Yuxin Wang, Bingwei Wang, Jianfeng Shen et al. · 2025 · eLife
  13. Arginine methylation regulates Ewing sarcoma cell viability in a EWSR1::FLI1 dependent manner and provides a therapeutic opportunity
    Ciara M. Ward, Charles Brockwell, Gavin S. McNee, Emily Orton, Emily N. P. Prowse, Susanne A. Gatz, Clare C. Davies · 2025 · Frontiers in Oncology
  14. Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens
    Silvia Fenoglio, Yi Yu, James Tepper, Lauren Grove, Alborz Bejnood, Samuel R. Meier, Ashley H Choi, Hsin‐Jung Wu, Annabel Devault, Shangtao Liu et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  15. Comprehensive non-small cell lung cancer targets: From computational prediction to clinical breakthroughs in overcoming drug resistance
    Wanjie Zheng, Zhiheng He, Jiarui Liu, Yuting Zhang, Chengjun Gong, Baojie Wang, Jie Shen, Li Guo, Tingming Liang · 2025 · Biochemical Pharmacology
  16. Enzymatic synthesis of stable isotope-labeled SAM for screening hMAT2A inhibitors by using matrix-assisted laser desorption/ionization mass spectrometry
    Lingna Zheng, Haiyu Lu, Qing Yang, Yixian Liu, Chunjing Chen, Q. J. Li, Xiang Gao · 2025 · The Analyst
  17. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
    Youyou Zhang, Mu Xu, Jiao Yuan, Zhongyi Hu, Junjie Jiang, Yanrong Sun, Jie Sheng Huang, Yuxin Wang, Bingwei Wang, Jianfeng Shen et al. · 2025 · eLife
  18. Thermodynamics of transition state analogs
    Vern L. Schramm, Ashleigh S. Paparella · 2025 · Elsevier eBooks
  19. A patent review of topoisomerase 1 inhibitors (2021–present)
    Marı́a Fuertes, Endika Martín‐Encinas, Asier Selas, Concepción Alonso · 2025 · Expert Opinion on Therapeutic Patents
  20. Clinical Impact of MTAP Rearrangement in Pediatric Acute Lymphoblastic Leukemia: Insights From Whole Transcriptome Analysis
    Sidong Zhang, Zhengyu Wu, Yufeng Liu, Bai Li, Yadong Song · 2025 · Pediatric Blood & Cancer
  21. Additional file 1 of Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
    Dominici, Claudia, Nicolas Sgarioto, Zhenbao Yu, Laura Sesma-Sanz, Jean‐Yves Masson, Stéphane Richard, Noël J.‐M. Raynal · 2021 · Figshare
  22. Discovery of Bis-Acyl Hydrazides as Potent and Bioavailable MTA-Cooperative PRMT5 Inhibitors: A Case Study of Leveraging the Deuterium Kinetic Isotope Effect
    Laurent Debien, Megan K. Armstrong, Joshua D. Farr, Ryan Ferrao, Pancham Lal Gupta, Congrong Niu, Andrew J. Anderson, Phillip Benner, Ashleigh N. Bristol, Elbert Chin et al. · 2025 · Journal of Medicinal Chemistry
  23. Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer
    Takashi Sakai, Zofia Piotrowska, Charlotte I. Wang, Beow Yong Yeap, Rebecca Suk Heist, Jessica J. Lin, Lauren Highfield, Jennifer L. Petersen, Mandeep K. Banwait, Joyce H. Liang et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  24. CRISPR-enabled genetic screens identify synthetic lethal targets across frequently altered cancer drivers
    Jessica Desjardins, Julian Bowlan, Cynthia Bernier, Srishti Jain, Théo Goullet de Rugy, David Gallo, Mark E. Orcholski, Nancy Laterreur, Abira Rajah, Joshua Miller et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  25. Prognostic Significance of Abnormal MTAP and p16 Expression in Gastrointestinal Stromal Tumors (GISTs)
    Azfar Neyaz, Nuha Shaker, Mohammad-Nasan Abdul-Baki, Hamdi Surakji, Rayan Rammal, Mariel Bedell, Ihsan Baroudi, Akila Mansour, Andrew M. Bellizzi, Ibrahim M. Abukhiran · 2026 · Applied immunohistochemistry & molecular morphology
  26. Inhibition of PRMT5-dependent YAP methylation attenuates tumorigenicity and radioresistance in glioblastoma
    Mei Luo, Shiyu Wu, Chenxin Huang, Ziyuan Zheng, Qiaoxi Xia, Yonghua Li, Xiao Zhou, Shihong Hong, Ronghui Zhong, Weijie Li et al. · 2026 · Cancer Letters
  27. PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath Tumors
    Dingxun Wang, Melissa L. Fishel, Azadeh Samiei, Silpa Gampala, Chang‐Deng Hu, Shaoxiong Chen, Guangjun Zhang · 2026 · SSRN Electronic Journal
  28. Cancer biology and the principles of targeted cancer drug discovery
    A. Davies, G. Jones, S. Krishnan, M. Krishnamoorthy, M. Maruggi, M. Kaneda, K. Marjon · 2026 · Elsevier eBooks
  29. Identification of a lineage-agnostic splicing signature caused by PRMT5 inhibition
    Matthew R. Tonini, Samuel R. Meier, Shangtao Liu, Kevin M. Cottrell, John P. Maxwell, Jannik N. Andersen, Alan Huang, Luisa Cimmino, Kimberly J. Briggs · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  30. Analysis of the Protein Arginine Methyltransferases 1 (PRMT1) and 4 (PRMT4) in Triple-Negative Breast Cancer
    Samyuktha Suresh · 2021
  31. Nucleic acid metabolism as therapeutic target in cancer: a comprehensive analysis of folate cycle, nucleotide synthesis, and clinical applications
    Jacinta DSouza, Harish Kundaikar · 2026 · Elsevier eBooks
  32. Investigating PRMT5 functions in triple-negative breast cancers
    Rayan Dakroub · 2023
  33. Meeting report on FASEB protein arginine methylation: mechanism to therapeutics
    David Shechter, Rong Huang, Pooja Anil Shah, Thierry Dubois, Xiao-Meng Li, Andrey A. Parkhitko, Mark T. Bedford, Shihuan Kuang, Taiping Chen, Yanzhong Yang et al. · 2026 · Journal of Biological Chemistry
  34. Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies
    Riccardo Bevilacqua, Paola Gasperini, Thomas Cantore, Catarina Macedo‐Silva, Michael Pancher, Martina Radić, Haiyan Yue, Orsetta Quaini, Tarcisio Fedrizzi, Pamela Gatto et al. · 2026 · npj Precision Oncology
  35. TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD- Deleted Cancers
    Hilary Elaine Nicholson, Douglas A. Whittington, Frank J. Bruzzese, Katherine Lazarides, Lauren Catherine M. Martires, Matthew R. Tonini, Helena N. Jenkins, Minjie Zhang, Preksha Shahagadkar, Charlotte B. Pratt et al. · 2026 · Cancer Discovery
  36. Mechanistic Investigation of a Domino N–H and C–H Borylation in the Manufacture of AMG 193
    Conner V. Wilson, Maria Victoria Silva Elipe, Sharon E. Michalak, Ted C. Judd, Neil F. Langille, James I. Murray · 2026 · Organic Process Research & Development
  37. Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer
    Rongjie Fu, Yalong Wang, Ishita Rehman, Ella Bedford, Sana Sharif, Nghi D. Nguyen, Reid Trenton Powell, Andrew Adams, W LIU, Shuyue Wang et al. · 2026 · Biomolecules
  38. Design and Discovery of Pyridazinone-Based MAT2A Inhibitors Targeting MTAP-Deficient Cancers
    Yu Zhang, Pengfei Wang, Zhicheng Xie, Yilun Huang, Yaqi Ding, Jia Liu, Yi Chen, Youhong Hu · 2026 · Journal of Medicinal Chemistry
  39. Targeting purinergic signaling and MTAP-associated metabolism in cancer: A functional immunometabolic convergence framework
    Vandriel P. da Rosa, Michelli Fontana, Carine Raquel Richter Schmitz, Maike V. Buzatto, Iuri Raiel Giacomelli, Walter Antônio Roman, Detlev Boison, Margarete Dulce Bagatini, Sarah Franco Vieira de Oliveira Maciel · 2026 · Biochemical Pharmacology
  40. MTAP loss in gallbladder carcinoma: frequency, heterogeneity and expression in precursor lesions
    Valentina Angerilli, Jessica Gasparello, Monia Niero, Giacomo Zanus, Matteo Fassan · 2026 · Journal of Clinical Pathology
  41. Structure-based discovery of a highly potent, selective, and brain-penetrant MTA-cooperative PRMT5 synthetic lethal inhibitor for the treatment of glioblastoma
    Bang Li, Xingcan Wang, Jinqi Yu, Qinfa Xie, Qiongyu Shi, Shuxian Li, Meiyu Geng, Xun Huang, Yuanxiang Wang, Hong Yang · 2026 · European Journal of Medicinal Chemistry
  42. Molecular Biomarkers in Urothelial Carcinoma: Current Insights and Future Directions
    Emanuele Crupi, Daniele Raggi, Arlene Odelia Siefker-Radtke, Jianjun Gao · 2026 · Cancer drug discovery and develogment/Cancer drug discovery and development
  43. MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy
    Hiroaki Ikushima, Hidenori Kage · 2026 · Cancer Science
  44. A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
    Filemon S. Dela Cruz, Daoqi You, Tamar Y. Feinberg, Samantha Brosius, Xinyi Wang, Joseph G.W. McCarter, Dylan Domenico, Jesús Gutiérrez‐Abril, Juan Arango Ossa, Gunes Gundem et al. · 2026 · Cancer Research
  45. Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications
    Peiwen Yang, Xin-Yi Xu, Ju-Ying Jiao, Fang Wang, Z Chen · 2026 · Experimental Hematology and Oncology
  46. Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights From a Large-Scale Real-World Chinese Cohort
    Qianhui Wei, Youhui Wang, Ting Hou, Qianxi Wang, Bo Lu, Lu Zhang, Chenglin Liu, Ting Kuang, Xinyan Li, He Jiang et al. · 2026 · Journal of Thoracic Oncology
  47. Synthetic lethality targets in pancreatic ductal adenocarcinoma: prevalence and limitations of liquid biopsy detection in a minority-serving cancer center
    Mahmoud Abdelsamia, Yafang Li, Daniel Eastwood, Ian Rabinowitz · 2026 · Future Oncology
  48. Tumoral Metabolism at the Intersection of Oncogene Signaling, Epigenetics and Immunology: Emerging Therapeutic Strategies in Cancer
    Bhoomendra A. Bhongade, Areeg Anwer Ali, Mohamed El‐Tanani, Shakta Mani Satyam, Sirajunisa Talath, Adil Farooq Wali, Syed Arman Rabbani, Walaa Ibraheem, Karolina Hoffmann, Авагимян Ашот Арманович et al. · 2026 · Current Issues in Molecular Biology
  49. Arginine Methylation in Alternative Splicing: Implications for Cancer Therapy
    Youyue Li, S Y Chen, Wenbo Ding, Bei Pan, Yujuan Yin, Xiaoqi Xin, Die Xia, Xueyang Wei, Siqi Bao, Mei‐Yan Xu · 2026 · Journal of Cellular Physiology
  50. Recurrent Uterine Smooth Muscle Tumor of Uncertain Malignant Potential in a Postmenopausal Woman After Total Abdominal Hysterectomy With Bilateral Salpingo‐Oophorectomy: A Case Report
    Ania Mezouari, Yaritza Gonzalez Ruiz, Anthony Serici, Virginia Fernandez, Guido Santacana‐Laffitte, Vangie Texidor · 2026 · Case Reports in Pathology
  51. A highly selective 1,2-dihydroquinoxaline derivative as a potent PRMT5-MTA complex inhibitor
    Yiru Liu, Zhihao Jiao, Daoguang Zhang, Xiaoxi Xu, Ye Jia, Hongjun Wang, Guisen Zhao · 2026 · Bioorganic & Medicinal Chemistry
  52. Discovery of a Potent, Selective, and Orally Bioavailable Achiral MAT2A Inhibitor for Treating MTAP-Deficient Cancers
    Lijie Lin, Zhiyin Xie, Jiayue Liu, Zhehuan Fan, Zihan Shi, 孙要良, Kexin Lin, Rongrong Cui, Xinyu Jiang, Xiaomin Luo et al. · 2026 · Journal of Medicinal Chemistry
  53. Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
    Valentina Spielmann, Jonas Buchloh, Selen Selcen, Carolin Schneider, Shaishavi Jansari, Xin Fang, Ningjun Duan, Engin Demirdizen, Lukas Krauß, Jessica Eggert et al. · 2026 · Cancer Research Communications
  54. Structure of an inhibitor bound to the catalytically important divalent metal ion site of afRioK1
    Daniel A. Hunter, Wenbo Yu, Purushottamachar Puranik, Aditi Bannerjee, Edwin Pozharski, Nishat Seraj, Mina Chang, Joanna Cooper, Dudley K. Strickland, Vanshika Dave et al. · 2026 · Journal of Structural Biology
  55. Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy
    Hongmei Li, Kunzhong Zhou, Ruiting Xu, Weifang Wang, Tingting Song, Yonghong Zhou, Jing Ren, Zhiyong Wang, Yiteng Liang, Yilin Chen et al. · 2026 · Frontiers in Oncology
  56. Arginine methylation as a regulatory ratchet in cancer: From substrate selection to malignant‐state stabilization
    So Hyun Kwon, Ji Min Lee · 2026 · Molecular Oncology
  57. Genome-wide CRISPR screens map synthetic lethal interactions across recurrent cancer driver alterations
    Jessica Desjardins, Julian Bowlan, Cynthia Bernier, Srishti Jain, Théo Goullet de Rugy, David Gallo, Mark E. Orcholski, Nancy Laterreur, Abira Rajah, Joshua Miller et al. · 2026 · Cell Reports
  58. Synthetic Lethality in Cancer Therapy
    Satya Swaroop Nune, Swagata Halder · 2026 · Elsevier eBooks
  59. The Methionine-Mitochondria Axis in Cancer: Metabolic Cross-Talk and Therapeutic Vulnerabilities
    Md Salman Shakil, Matthew J. McBride · 2026 · Current Pharmacology Reports
  60. Next-generation tumor-agnostic targets on the horizon
    Niamh Coleman, Jia Liu, Juliana Rodrigues Beal, Vivek Subbiah · 2026 · Trends in cancer
  61. Immunohistochemistry Resolves Indeterminate MTAP Deletion Calls From Exome Sequencing: A Pan-Cancer Concordance Study
    Marion Thibaudin, Julie Lecuelle, Anthony Bergeron, Valentin Derangere, Hugo Mananet, Léa Hampe, Susy Daumoine, Sandy Chevrier, Ana Costa, Natacha Moulharat et al. · 2026 · Modern Pathology
  62. Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation
    Cristina Camps-Fajol, Jordi Minguillón, Jordi Surrallés · 2026 · Signal Transduction and Targeted Therapy
  63. Purine Metabolism as a Therapeutic Target in Glioblastoma
    Noah B. Drewes, Yiting Xu, Priya Kumthekar, Atique U. Ahmed · 2026 · Hematology/Oncology Clinics of North America
  64. Discovery of GTA182, a Novel CNS-Active Tricyclic Amide MTA-Cooperative PRMT5 Inhibitor for MTAP -Deleted Cancers
    Bing Yao, Weifeng Mao, 王明华, Junqing Zhang, Shanshan Xie, Kai Cheng, Xinbo Hu, Wei Liu, Xiangping Zhang, Zhu Zhengqing et al. · 2026 · Journal of Medicinal Chemistry
  65. Targeting protein arginine methyltransferases to enhance cancer immunotherapy
    Nivine Srour, Chunxiao Zhao, Stéphane Richard · 2026 · Cell chemical biology
  66. Calvarial erosion secondary to epithelioid glioblastoma: A molecularly characterized case report
    Abdulrahman M. Khojah, Ali Alkhaibary, Fahd AlSufiani, Ali H. Alassiri, Ahmed M. Alkhani · 2026 · Surgical Neurology International
  67. MTAP Loss and Pleural Mesothelioma (PM): Current Treatment Strategies and Emerging Therapeutic Approaches
    S. Cedrés, Laura Masfarré, Ilaria Priano, Augusto Valdivia, Pedro Rocha, Patricia Iranzo, Núria Pardo, Alex Martínez‐Martí, Aina Arbusà, Lucía Cané et al. · 2026 · Cancers
  68. Expanding DepMap: is the juice worth the squeeze?
    S. Zaidi, Charles L. Sawyers · 2026 · Cell Research
  69. Features of cancer cell metabolism linked to DNA repair mechanisms.
    R. Mikheeva, P. Leonov, M. Koryukov, Ekaterina Ruleva, Xue-Song Liu, A. Kechin · 2026 · DNA Repair
  70. BindingDB Entry 50008922: Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.
    BindingDB · 2021 · UC San Diego
  71. BindingDB Entry 50014992: Fragment-Based Design of a Potent MAT2a Inhibitor and
    BindingDB · 2023 · UC San Diego
  72. BindingDB Entry 50017717: Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads.
    BindingDB · 2023 · UC San Diego
  73. BindingDB Entry 50007537: Selective Inhibitors of Helicobacter pylori Methylthioadenosine Nucleosidase and Human Methylthioadenosine Phosphorylase.
    BindingDB · 2021 · UC San Diego
  74. BindingDB Entry 50020273: Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening.
    BindingDB · 2024 · UC San Diego
  75. BindingDB Entry 50020674: Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability.
    BindingDB · 2024 · UC San Diego
  76. BindingDB Entry 50021285: Development of a Series of Pyrrolopyridone MAT2A Inhibitors.
    BindingDB · 2025 · UC San Diego
  77. BindingDB Entry 50016955: Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors.
    BindingDB · 2023 · UC San Diego
  78. BindingDB Entry 50023341: From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy.
    BindingDB · 2026 · UC San Diego
  79. BindingDB Entry 50018799: Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
    BindingDB · 2024 · UC San Diego
  80. BindingDB Entry 50002756: Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
    BindingDB · 2020 · UC San Diego
  81. BindingDB Entry 50023053: Discovery of 2(1H)-Quinoxalinone Derivatives as Potent and Selective MAT2A Inhibitors for the Treatment of MTAP-Deficient Cancers.
    BindingDB · 2026 · UC San Diego
  82. BindingDB Entry 50015337: Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of
    BindingDB · 2023 · UC San Diego
  83. BindingDB Entry 50017921: Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.
    BindingDB · 2023 · UC San Diego
  84. BindingDB Entry 50023240: Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers.
    BindingDB · 2026 · UC San Diego
  85. BindingDB Entry 50022937: Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity.
    BindingDB · 2026 · UC San Diego
  86. BindingDB Entry 50021728: Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers.
    BindingDB · 2025 · UC San Diego
  87. BindingDB Entry 50020883: Discovery of Potent and Oral Bioavailable MAT2A Inhibitors for the Treatment of MTAP-Deleted Tumors.
    BindingDB · 2024 · UC San Diego
  88. BindingDB Entry 50006690: Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors.
    BindingDB · 2021 · UC San Diego
  89. BindingDB Entry 50014417: Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous
    BindingDB · 2022 · UC San Diego
  90. BindingDB Entry 50022533: Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
    BindingDB · 2025 · UC San Diego
  91. BindingDB Entry 50015922: Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.
    BindingDB · 2023 · UC San Diego
  92. BindingDB Entry 50021894: Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity.
    BindingDB · 2025 · UC San Diego
  93. BindingDB Entry 50012652: Exploiting binding-site arginines in drug design: Recent examples.
    BindingDB · 2022 · UC San Diego
  94. BindingDB Entry 50020264: Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
    BindingDB · 2024 · UC San Diego
  95. BindingDB Entry 50019870: Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies.
    BindingDB · 2024 · UC San Diego
  96. BindingDB Entry 50020979: New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives.
    BindingDB · 2025 · UC San Diego
  97. BindingDB Entry 50013473: The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer.
    BindingDB · 2022 · UC San Diego
  98. BindingDB Entry 50021531: Identification of a Sonically Activated Degrader of Methionine Adenosyltransferase 2A by an in Silico Approach Assisted with the Hole-Electron Analysis.
    BindingDB · 2025 · UC San Diego
  99. Azolo[1,5-a]pyrimidines as a promising platform for the development of antitumour agents. Structure–activity relationship
    Evgeny M. Mukhin, Konstantin V. Savateev, Eva V. Bersneva, Сергей В. Андронов, В. Л. Русинов · 2026 · Russian Chemical Reviews